Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
November 13, 2024 07:00 ET
|
Tenax Therapeutics
Raised Gross Proceeds of Approximately $100 Million in a Private Placement with Leading Institutional Healthcare Investors Continuing to Enroll Patients in Phase 3 LEVEL Study with 52 Investigative...
Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference
October 31, 2024 16:05 ET
|
Tenax Therapeutics
CHAPEL HILL, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and...
Tenax Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
August 13, 2024 16:05 ET
|
Tenax Therapeutics
Raised Gross Proceeds of Approximately $100 Million in a Private Placement with Leading Institutional Healthcare Investors Continuing to Enroll Patients in Phase 3 LEVEL Study with 39 Investigative...
Tenax Therapeutics Announces Closing of $100 Million Private Placement and Plans to Accelerate the Oral Levosimendan Phase 3 Program
August 12, 2024 08:00 ET
|
Tenax Therapeutics
• Funding supports advancement of oral levosimendan (TNX-103) Phase 3 development program, including completion of the ongoing LEVEL Study for the treatment of Pulmonary Hypertension Due to Heart...
Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement
August 06, 2024 07:13 ET
|
Tenax Therapeutics
CHAPEL HILL, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (the “Company” or “Tenax Therapeutics”), a Phase 3, development-stage pharmaceutical company focused on...
Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
May 14, 2024 08:00 ET
|
Tenax Therapeutics
Currently Enrolling Patients in Phase 3 LEVEL Study with 24 Investigative Sites Initiated Secured Global Development and Commercial Rights to Levosimendan for Treatment of PH-HFpEF ...
Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
April 30, 2024 07:30 ET
|
Tenax Therapeutics
Broadens IP protection for oral (TNX-103), IV, and subcutaneous use of levosimendan, and its active metabolites (OR1896 and OR1855), in PH-HFpEFProvides U.S. intellectual property (IP) protection...
Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”
April 09, 2024 08:30 ET
|
Tenax Therapeutics
Panel of renowned cardiologists, all globally recognized experts in heart failure, will discuss the unmet medical need in pulmonary hypertension due to heart failure with preserved ejection fraction...
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results
March 28, 2024 08:30 ET
|
Tenax Therapeutics
First Patient Enrolled in Phase 3 LEVEL Trial Evaluating TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension from Heart Failure with Preserved Ejection Fraction (PH-HFpEF)Expansion...
Tenax Therapeutics to Present at the 36th Annual Roth Conference
March 12, 2024 08:30 ET
|
Tenax Therapeutics
CHAPEL HILL, N.C., March 12, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and...